JP2004507500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507500A5 JP2004507500A5 JP2002522887A JP2002522887A JP2004507500A5 JP 2004507500 A5 JP2004507500 A5 JP 2004507500A5 JP 2002522887 A JP2002522887 A JP 2002522887A JP 2002522887 A JP2002522887 A JP 2002522887A JP 2004507500 A5 JP2004507500 A5 JP 2004507500A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- inclusive
- alkyl
- aryl
- carboxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 26
- 125000003118 aryl group Chemical group 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 230000002265 prevention Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 201000002222 hemangioblastoma Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 206010028537 myelofibrosis Diseases 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 208000017497 prostate disease Diseases 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 229910003850 O-nPr Inorganic materials 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22780300P | 2000-08-25 | 2000-08-25 | |
| US60/227,803 | 2000-08-25 | ||
| US27845501P | 2001-03-23 | 2001-03-23 | |
| US60/278,455 | 2001-03-23 | ||
| US09/935,285 US6630500B2 (en) | 2000-08-25 | 2001-08-22 | Selected fused pyrrolocarbazoles |
| US09/935,285 | 2001-08-22 | ||
| PCT/US2001/026266 WO2002017914A2 (en) | 2000-08-25 | 2001-08-23 | Fused pyrrolocarbazoles against inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004507500A JP2004507500A (ja) | 2004-03-11 |
| JP2004507500A5 true JP2004507500A5 (enExample) | 2008-10-09 |
| JP5399598B2 JP5399598B2 (ja) | 2014-01-29 |
Family
ID=27397767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002522887A Expired - Fee Related JP5399598B2 (ja) | 2000-08-25 | 2001-08-23 | 炎症に対する縮合ピロロカルバゾール |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6630500B2 (enExample) |
| EP (1) | EP1311263B1 (enExample) |
| JP (1) | JP5399598B2 (enExample) |
| KR (1) | KR100810190B1 (enExample) |
| CN (1) | CN1298323C (enExample) |
| AR (1) | AR034143A1 (enExample) |
| AT (1) | ATE306920T1 (enExample) |
| AU (1) | AU8520501A (enExample) |
| BG (1) | BG66103B1 (enExample) |
| BR (1) | BR0113776A (enExample) |
| CA (1) | CA2420592C (enExample) |
| CZ (1) | CZ303707B6 (enExample) |
| DE (1) | DE60114215T2 (enExample) |
| DK (1) | DK1311263T3 (enExample) |
| EA (1) | EA006371B1 (enExample) |
| ES (1) | ES2250463T3 (enExample) |
| HU (1) | HU230128B1 (enExample) |
| IL (2) | IL154590A0 (enExample) |
| MX (1) | MXPA03001562A (enExample) |
| NO (1) | NO325689B1 (enExample) |
| NZ (1) | NZ524288A (enExample) |
| PL (1) | PL212956B1 (enExample) |
| SK (1) | SK287498B6 (enExample) |
| TW (1) | TWI299731B (enExample) |
| WO (1) | WO2002017914A2 (enExample) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| EA015363B1 (ru) | 2003-07-18 | 2011-06-30 | Эмджен Инк. | Агенты, специфически связывающие фактор роста гепатоцитов, и их применение |
| US7169802B2 (en) * | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US7241779B2 (en) * | 2003-12-23 | 2007-07-10 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008086014A2 (en) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| WO2008151323A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| CN103965204B (zh) * | 2008-11-19 | 2016-09-07 | 赛福伦公司 | 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式 |
| EP2192121A1 (en) | 2008-11-27 | 2010-06-02 | Cephalon France | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones |
| KR101038055B1 (ko) * | 2010-06-10 | 2011-06-01 | 송광섭 | 수중 마사지장치 |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| JP7041515B2 (ja) | 2015-01-08 | 2022-03-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞 |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP7454572B2 (ja) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| AU2019404576B2 (en) | 2018-12-20 | 2025-07-17 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| JP7699100B2 (ja) | 2019-08-02 | 2025-06-26 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| MX428368B (es) | 2019-08-02 | 2025-11-13 | Amgen Inc | Inhibidores de kif18a |
| AU2020325115B2 (en) | 2019-08-02 | 2026-03-12 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
| US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| AU2020369569B2 (en) | 2019-10-24 | 2026-06-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| PH12022551102A1 (en) | 2019-11-08 | 2023-11-20 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| EP4700030A3 (en) | 2019-11-14 | 2026-03-18 | Amgen, Inc. | Improved synthesis of kras g12c inhibitor compound |
| CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| CA3163703A1 (en) | 2020-01-07 | 2021-07-15 | Steve Kelsey | Shp2 inhibitor dosing and methods of treating cancer |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| KR20240156373A (ko) | 2022-03-07 | 2024-10-29 | 암젠 인크 | 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4514998A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| IL320217A (en) | 2022-10-14 | 2025-06-01 | Black Diamond Therapeutics Inc | Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives |
| CN120752534A (zh) | 2023-03-17 | 2025-10-03 | 瑞泽恩制药公司 | 骨关节炎(oa)的蛋白质组学风险评分 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024404879A1 (en) | 2023-12-22 | 2026-06-25 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552842A (en) | 1983-01-28 | 1985-11-12 | Bristol-Myers Company | Process for producing rebeccamycin |
| US5438050A (en) | 1988-02-06 | 1995-08-01 | Godecke Aktiengesellschaft | Indolocarbazole derivatives, processes for their preparation and compositions containing them |
| US5185260A (en) | 1991-08-29 | 1993-02-09 | The United States Of America As Represented By The United States Department Of Energy | Method for distinguishing normal and transformed cells using G1 kinase inhibitors |
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5475110A (en) | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5594009A (en) | 1994-10-14 | 1997-01-14 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5705711A (en) * | 1995-08-17 | 1998-01-06 | Huntsman Specialty Chemicals Corporation | Manufacture of methyl tertiary butyl ether in reactive distillation column |
| US5808060A (en) | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
| US5616724A (en) | 1996-02-21 | 1997-04-01 | Cephalon, Inc. | Fused pyrrolo[2,3-c]carbazole-6-ones |
| BR9711306A (pt) | 1996-08-22 | 1999-08-17 | Bristol Myers Squibb Co | Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis |
| US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
| HK1040053B (en) | 1998-09-25 | 2007-09-21 | Cephalon, Inc. | Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons |
| US6841567B1 (en) | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
-
2001
- 2001-08-22 US US09/935,285 patent/US6630500B2/en not_active Expired - Lifetime
- 2001-08-23 CN CNB018146333A patent/CN1298323C/zh not_active Expired - Fee Related
- 2001-08-23 HU HU0303103A patent/HU230128B1/hu not_active IP Right Cessation
- 2001-08-23 EP EP01964340A patent/EP1311263B1/en not_active Expired - Lifetime
- 2001-08-23 CA CA2420592A patent/CA2420592C/en not_active Expired - Fee Related
- 2001-08-23 DE DE60114215T patent/DE60114215T2/de not_active Expired - Lifetime
- 2001-08-23 IL IL15459001A patent/IL154590A0/xx unknown
- 2001-08-23 MX MXPA03001562A patent/MXPA03001562A/es active IP Right Grant
- 2001-08-23 TW TW090120678A patent/TWI299731B/zh not_active IP Right Cessation
- 2001-08-23 KR KR1020037002676A patent/KR100810190B1/ko not_active Expired - Fee Related
- 2001-08-23 WO PCT/US2001/026266 patent/WO2002017914A2/en not_active Ceased
- 2001-08-23 JP JP2002522887A patent/JP5399598B2/ja not_active Expired - Fee Related
- 2001-08-23 PL PL365683A patent/PL212956B1/pl unknown
- 2001-08-23 AR ARP010104016A patent/AR034143A1/es not_active Application Discontinuation
- 2001-08-23 BR BR0113776-0A patent/BR0113776A/pt not_active Application Discontinuation
- 2001-08-23 NZ NZ524288A patent/NZ524288A/en unknown
- 2001-08-23 DK DK01964340T patent/DK1311263T3/da active
- 2001-08-23 AT AT01964340T patent/ATE306920T1/de active
- 2001-08-23 SK SK219-2003A patent/SK287498B6/sk not_active IP Right Cessation
- 2001-08-23 AU AU8520501A patent/AU8520501A/xx active Pending
- 2001-08-23 ES ES01964340T patent/ES2250463T3/es not_active Expired - Lifetime
- 2001-08-23 EA EA200300293A patent/EA006371B1/ru not_active IP Right Cessation
- 2001-08-23 CZ CZ20030539A patent/CZ303707B6/cs not_active IP Right Cessation
-
2003
- 2003-02-24 NO NO20030845A patent/NO325689B1/no not_active IP Right Cessation
- 2003-03-21 BG BG107659A patent/BG66103B1/bg unknown
- 2003-03-26 US US10/400,136 patent/US7115613B2/en not_active Expired - Fee Related
-
2006
- 2006-02-08 US US11/350,170 patent/US7230026B2/en not_active Expired - Fee Related
-
2008
- 2008-04-27 IL IL191104A patent/IL191104A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2420592A1 (en) | Fused pyrrolocarbazoles against inflammation | |
| JP2022533912A5 (enExample) | ||
| RU2003128535A (ru) | Гетерополициклическое соединение (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, ассоциированного с активацией метаботропных глютаматных рецепторов (варианты) | |
| JP6298765B2 (ja) | 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物 | |
| JP2019518766A5 (enExample) | ||
| JP2005505506A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| RU2019126848A (ru) | Способы производства дейтерий-обогащённого N-ацетилцистеин амида (D-NACA) и (2R,2R')-3,3'-дисульфанедиил бис(2-ацетамидопропанамида) (DINACA) и применение D-NACA и DINACA для лечения заболеваний, включающих окислительный стресс | |
| CA2413134A1 (en) | Quinazoline ditosylate salt compounds | |
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| WO2010115836A4 (en) | Substituted piperidines as ccr3 antagonists | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2005516067A5 (enExample) | ||
| JP4441677B2 (ja) | アミノ酸誘導体 | |
| JP2002516865A5 (enExample) | ||
| JP2007504128A5 (enExample) | ||
| JP2012509279A5 (enExample) | ||
| WO2021111462A1 (en) | An improved process for the preparation of osimertinib mesylate | |
| JP2022513933A5 (enExample) | ||
| JP2008508248A5 (enExample) | ||
| DE69819206T2 (de) | Matrixmetalloproteinaseinhibitoren | |
| JP2008505980A (ja) | イソブチルグルタル酸を有さないプレガバリン及びその調製方法 | |
| JP2020507567A5 (enExample) | ||
| RU2019128576A (ru) | Сокристаллы замещенных глициновых соединений и их применение | |
| JP2019535715A5 (enExample) |